Lv3
298 积分 2021-10-14 加入
[Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer]
10小时前
已完结
[Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version)]
16小时前
已完结
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
12天前
已完结
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
14天前
已完结
Targeting Trop-2 as a Cancer Driver
1个月前
已完结
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
1个月前
已完结
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
1个月前
已完结
Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study
8个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
8个月前
已完结
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
8个月前
已完结
皖公网安备34019202002308
